CHEBI:183517 - LFM-A13

ChEBI IDCHEBI:183517
ChEBI NameLFM-A13
Stars
DefinitionAn enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.
Secondary ChEBI IDCHEBI:95065
Last Modified9 November 2021
SubmitterAdnan
DownloadsMolfile
FormulaC11H8Br2N2O2
Net Charge0
Average Mass360.005
Monoisotopic Mass357.89525
SMILESC/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br
InChIInChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
InChIKeyUVSVTDVJQAJIFG-VURMDHGXSA-N
Roles Classification
Biological Roles:
apoptosis inducer  Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor  An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2).
EC 2.7.11.21 (polo kinase) inhibitor  An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of any polo kinase (EC 2.7.11.21).
Applications:
antineoplastic agent  A substance that inhibits or prevents the proliferation of neoplasms.
platelet aggregation inhibitor  A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
geroprotector  Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
ChEBI Ontology
Outgoing Relation(s)
LFM-A13 (CHEBI:183517) has role antineoplastic agent (CHEBI:35610)
LFM-A13 (CHEBI:183517) has role apoptosis inducer (CHEBI:68495)
LFM-A13 (CHEBI:183517) has role EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor (CHEBI:76617)
LFM-A13 (CHEBI:183517) has role EC 2.7.11.21 (polo kinase) inhibitor (CHEBI:145425)
LFM-A13 (CHEBI:183517) has role geroprotector (CHEBI:176497)
LFM-A13 (CHEBI:183517) has role platelet aggregation inhibitor (CHEBI:50427)
LFM-A13 (CHEBI:183517) is a aromatic amide (CHEBI:62733)
LFM-A13 (CHEBI:183517) is a dibromobenzene (CHEBI:37147)
LFM-A13 (CHEBI:183517) is a enamide (CHEBI:51751)
LFM-A13 (CHEBI:183517) is a enol (CHEBI:33823)
LFM-A13 (CHEBI:183517) is a nitrile (CHEBI:18379)
LFM-A13 (CHEBI:183517) is a secondary carboxamide (CHEBI:140325)
IUPAC Name 
(2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
Synonyms  Source
α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamideChEBI
DDE-28ChEBI
2Z-cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamideChEBI
(2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamideChEBI
Manual XrefsDatabases
LSM-6315LINCS
21171575ChemSpider
Registry NumbersSources
CAS:244240-24-2ChEBI
Citations